Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
45°
Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
49.13
-0.23 (-0.47%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Stock Split Watch: Is Regeneron Pharmaceuticals Next?
September 30, 2023
If the biotech does split its stock, it will be a first for the company.
Via
The Motley Fool
Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst
September 28, 2023
Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.
Via
Benzinga
Apple Defends Its $19B Google Search Deal, Hollywood's Writers Secure Credit For AI Training, China's Ambitious Chip Fund Faces Headwinds: Today's Top Stories
September 27, 2023
Benzinga Alibaba's Logistics Arm Cainiao Files For Hong Kong IPO
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Looking Into Sanofi's Recent Short Interest
September 18, 2023
Via
Benzinga
(SNY) - Analyzing Sanofi's Short Interest
August 29, 2023
Via
Benzinga
2 Top Biotech Stocks to Buy Right Now
August 14, 2023
These drugmakers are among the most dominant in the world.
Via
The Motley Fool
Why Shares of MacroGenics Are Jumping Thursday
August 10, 2023
The company announced second-quarter earnings.
Via
The Motley Fool
Weight Loss Drugs Like Wegovy Could Have Linked Anesthesia Complications, European Medicines Agency To Investigate
September 27, 2023
The European Medicines Agency (EMA) is set to address concerns related to patients taking drugs such as Novo Nordisk A/S's (NYSE
Via
Benzinga
Multi-Billion Dollar Treatment Market For Lung Infection That Causes Over 200,000 Hospitalizations Annually With Elderly, Young At Most Risk Has Game-Changing New Entrant
September 26, 2023
Read the latest report on NanoViricides here
Via
Benzinga
Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 Accepted for FDA Priority Review
September 26, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
CDC Backs Pfizer's RSV Infection Maternal Vaccine During Pregnancy As Protection For Infants
September 25, 2023
Friday, The Centers for Disease Control and Prevention recommended the first respiratory syncytial virus (RSV) vaccine for pregnant people to protect their newborns from severe RSV
Via
Benzinga
Looking Into Sanofi's Recent Short Interest
August 08, 2023
Via
Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
September 21, 2023
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
September 21, 2023
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday.
Via
Benzinga
Gold Down Over 1%; FedEx Shares Rise On Earnings Beat
September 21, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 150 points on Thursday. The Dow traded down 0.46% to 34,284.15 while the NASDAQ fell 1.05% to 13,327.80. The S&P 500...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Nasdaq Down Over 1%; US Initial Jobless Claims Fall More Than Expected
September 21, 2023
U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 150 points on Thursday. Following the market opening Thursday, the Dow traded down 0.56% to 34,248.45 while the NASDAQ fell...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Kidney-Disease Focused Travere Therapeutics Stock Trading Lower Today?
September 21, 2023
Travere Therapeutics Inc (NASDAQ: TVTX) announced
Via
Benzinga
Elon Musk-Backed Neuralink Starts Participant Enrollment For Paralysis, Eli Lilly Cracks Down on Counterfeit Weight Loss Drugs, Meta Looks to Capitalize on India's In-App Payment Surge: Today's Top Stories
September 20, 2023
Benzinga
Via
Benzinga
FDA Rejects EpiPen Alternative - ARS Pharmaceuticals' Allergic Reaction Nasal Spray
September 20, 2023
The FDA issued a Complete Response Letter regarding ARS Pharmaceuticals Inc's (NASDAQ: SPRY) New Drug Application (NDA) for neffy (epinephrine nasal spray) in the treatment of Allergic Reactions (Type...
Via
Benzinga
Exposures
Product Safety
3 Stocks to Buy to Ride Europe’s Coming Market Surge
September 19, 2023
With Europe’s markets looking to perform better in the second half of 2023, here are three European stocks to buy to ride the wave.
Via
InvestorPlace
Moderna's R&D Day Unveils Strategic Roadmap Beyond COVID Franchise: Goldman Sachs
September 14, 2023
On Wednesday, Moderna Inc (NASDAQ: MRNA) conducted an R&D Day event outlining its strategic initiatives across four key areas - Respiratory Vaccines, Latent/Other Vaccines, Oncology Therapeutics,
Via
Benzinga
Exposures
COVID-19
This Market Could Be Worth $10 Billion by 2030 -- 2 Stocks to Buy Now
September 14, 2023
This market is currently in its infancy.
Via
The Motley Fool
'Transformative Event' For First Wave BioPharma: License Agreement for Hopeful Gastrointestinal Candidate From Sanofi
September 14, 2023
First Wave BioPharma Inc (NASDAQ: FWBI) announced an agreement with Sanofi SA (NASDAQ: SNY) to license Capeserod, a selective 5-HT4 receptor partial agonist, which First Wave will repurpose and develop...
Via
Benzinga
Flu Vaccine Results Give Moderna (MRNA) Stock a Shot in the Arm
September 13, 2023
Moderna released encouraging results for its late-stage trial of its flu vaccine. Now, MRNA stock is looking like more than a one-trick pony.
Via
InvestorPlace
Moderna Stock Has Been Beaten Up; Why The CFO Says Its Story Is 'Misunderstood'
September 13, 2023
Moderna unveiled promising results in flu on Wednesday, adding to its respiratory suite.
Via
Investor's Business Daily
Could This Medicine Be the Next Winner for Novartis?
August 23, 2023
The Swiss drugmaker recently reported that a drug candidate met the primary endpoints in phase 3 clinical trials.
Via
The Motley Fool
FDA Greenlights Pfizer's RSV Vaccine: Moms Can Now Protect Babies Before Birth
August 22, 2023
Monday, the FDA approved Pfizer Inc's (NYSE: PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company's bivalent RSV prefusion F (RSVpreF) vaccine, to prevent the infection in infants from birth...
Via
Benzinga
Exposures
Product Safety
Is Regeneron Pharmaceuticals Still a Top Growth Stock?
August 21, 2023
The biotech's focus on innovation could be a boon for shareholders.
Via
The Motley Fool
2 Biotech Stocks That Could Make You Richer
August 18, 2023
Neither is performing particularly well this year compared to the broader market, but don't let that chase you away.
Via
The Motley Fool
Amazon's Boon for Diabetes Patients - Streamlining Pharmacy Discounts
August 15, 2023
Amazon.Com Inc's (NASDAQ: AMZN) online pharmacy launched a new initiativ
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
26
27
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.